Superworth

DocGo EPS DCGO

Diluted earnings per share by quarter and over the last twelve months, from 2021.

Last 12 months, to Jun 30, 2026
−$1.96
Latest quarter, Q2 FY26
−$0.16
Fiscal year 2025
−$1.85
−1128% on the year before

DocGo's earnings per share was −$1.96 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.16.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.85−1128%
FY2024$0.18+157%
FY2023$0.07−79%
FY2022$0.33n/a
FY2021−$18.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.16n/a−$1.96
Q1 FY26−$0.15n/a−$1.91
Q4 FY25−$1.37n/a−$1.85
Q3 FY25−$0.28−660%−$0.51
Q2 FY25−$0.11−283%−$0.18
Q1 FY25−$0.09−190%−$0.01
Q4 FY24−$0.03−143%$0.18
Q3 FY24$0.05+0%$0.28
Q2 FY24$0.06n/a$0.28
Q1 FY24$0.10n/a$0.20
Q4 FY23$0.07−30%$0.07
Q3 FY23$0.05+67%$0.10

Against its peers

Companies in Healthcare nearest DocGo's size, closest first, today.

CompanyEPS, 12 monthsGrowth
DCGODocGo−$1.96
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ICCCImmucell$0.08−58% a year
KEQUKewaunee Scientific$2.76−33% a year
PDEXPro DEX$4.11+52% a year
PLXProtalix BioTherapeutics$0.23+283% a year
NATRNatures Sunshine Products$1.01+36% a year
Peer median$0.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on DocGo

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.